Rolling up its sleeves, Axovant scoops up five gene therapy vets to propel new pipeline

Having assembled a largely preclinical pipeline of gene therapies through a couple of licensing pacts, Axovant is expanding the crew charged with executing its high-stakes turnaround mission.